Antios rocked as hepatitis B safety signal sparks clinical hold, termination of collaboration

Antios Therapeutics’ push to develop a curative hepatitis B therapy has hit turbulence. The FDA has slapped Antios with a clinical hold over a safety report, prompting Assembly Biosciences to terminate its clinical trial collaboration agreement with the deep-pocketed biotech.